Genetic Theory of Cancer. Short Review

• Authors: Maria Sąsiadek , Paweł Karpiński
• Languages of publication: EN

Abstracts

EN

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2009
• Volume: 81
• Issue: 10
• Pages: 478-485

Dates

published

1 - 10 - 2009

online

25 - 11 - 2009

Contributors

author

Maria Sąsiadek

• Department of Genetics, Medical University, Wrocław

author

Paweł Karpiński

• Department of Genetics, Medical University, Wrocław

References

• Lynch HT, Smyrk T, Lynch J: An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet 1997; 93: 84-99.[PubMed][Crossref]
• Bronchud MH: Is cancer really a ‘local’ cellular clonal disease? Med Hypotheses 2002; 59(5): 560-65.[PubMed][Crossref]
• Fabarius A, Li R, Yerganian G et al.: Specific clones of spontaneously evolving karyotypes generate individuality of cancers. Cancer Genet Cytogenet 2008; 180(2): 89-99.[WoS][Crossref][PubMed]
• Gatenby RA, Vincent TL: An evolutionary model of carcinogenesis. Cancer Res 2003; 63(19): 6212-20.[PubMed]
• Gil J, Stembalska A, Pesz KA et al.: Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet 2008; 49: 193-99.[PubMed][WoS][Crossref]
• Park M: Oncogenes in the genetic basis of human cancer, 1998, ed. Vogelstein B., Kinzler K.W., McGrew-Hill Health Professional Division.
• Fearon EE: Tumor suppresor genes, in the genetic basis of human cancer, 1998, ed. Vogelstein B., Kinzler K.W. McGrew-Hill Health Professional Division.
• Eshelman JR, Marcowitz SD: Microsatellite instability in inherited and sporadic neoplasms. Current Opinion in Oncol 1995; 7(1): 83-89.
• Freisinger F, Domchek SM: Clinical implications of low-penetrance breast cancer susceptibility alleles. Curr Oncol Rep 2009; 11(1): 8-14.[PubMed][Crossref][WoS]
• Vineis P, Manuguerra M, Kavvoura FK et al.: A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 2009; 101(1): 24-36.[WoS][Crossref]
• Bignold LP: Carcinogen-induced impairment of enzymes for replicative fidelity of DNA and the initiation of tumours. Carcinogenesis 2004; 25(3): 299-307.[PubMed]
• Shields PG, Harris CC: Cancer Risk and Low-Penetrance Susceptibility Genes in Gene-Environment interactions. J Clin Oncol 2000; 18: 2309-15.[PubMed]
• Bignold LP: Cancer morphology, carcinogenesis and genetic instability: a background, EXS 2006; (96): 1-24.[PubMed]
• Wogan GN, Hecht SS, Felton JS et al.: Environmental and chemical carcinogenesis. Semin Cancer Biol 2004; 14(6): 473-86.[PubMed][Crossref]
• Grando JP, Kuasne H, Losi-Guembarovski R et al.: Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med 2009; 9(1): 21-28.[Crossref]
• Shen J: Evaluation of environmental and personal susceptibility characteristics that modify genetic risks. Methods Mol Biol 2009; 471: 163-77.[Crossref][PubMed]
• Tan DS, Marchiò C, Reis-Filho JS: Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol 2008; 61(10): 1073-82.[Crossref][PubMed]
• Easton DF, Pooley KA, Dunning AM et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007 28; 447(7148): 1087-93.
• Turnbull C, Rahman N: Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics. Hum Genet 2008; 9: 321-45.[Crossref][PubMed][WoS]
• Willems PJ: Susceptibility genes in breast cancer: more is less? Clin Genet 2007; 72: 493-96.[Crossref]
• Venkitaraman AR: Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114: 3591-58.[PubMed]
• Yee KS, Vousden KH: Complicating the complexity of p53. Carcinogenesis 2005; 26(8): 1317-22.[Crossref]
• Plass C: Cancer epigenomics. HumMol Genet 2002; 11: 2479-88.
• Laird PW: Cancer epigenetics. Hum Mol Genet 2005; 14: R65-R76.[Crossref]
• Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-66.[Crossref][PubMed]
• Kanai Y, Hirohashi S: Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007; 28: 2434-42.[Crossref][WoS][PubMed]
• Costello JF, Plass C: Methylation matters. J Med Genet 2001; 38: 285-303.[PubMed][Crossref]
• Herceg Z: Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007; 22: 91-103.[WoS][Crossref][PubMed]
• Karpinski P, Sąsiadek MM, Blin N: Aberrant epigenetic patterns in the etiology of gastrointestinal cancers. J Appl Genet 2008; 49: 1-10.[Crossref][PubMed][WoS]
• Esteller M: Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629-56.[Crossref][WoS][PubMed]
• Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-93.[Crossref][PubMed]
• Rodriguez J, Frigola J, Vendrell E et al.: Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 2006; 66: 8462-9468.[PubMed][Crossref]
• Clark JS: Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 2007; 16: R88-R95.[Crossref][WoS]
• Johnson CA: Chromatin modification and disease. J Med Genet 2000; 37: 905-15.[Crossref][PubMed]
• Zhang Y, Reinberg D: Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 23-43.
• Frigola J, Song J, Stirzaker C et al.: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38: 540-49.[PubMed][Crossref]
• Karpinski P, Ramsey D, Grzebieniak Z et al.: The CpG Island Methylator Phenotype Correlates with Long-Range Epigenetic Silencing in Colorectal Cancer. Mol Cancer Res 2008; 6: 585-91.[Crossref][PubMed]
• Griffiths-Jones S, Saini HK, van Dongen S et al.: miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36: D154 - D158.[WoS]
• Dalmay T, Edwards DR: MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25: 6170-75.[Crossref][PubMed]
• Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.[Crossref][PubMed]
• Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of Tumor-Suppressive MicroRNAs Silenced by DNA Hypermethylation in Oral Cancer. Cancer Res 2008; 68: 2094-2105.[Crossref][WoS][PubMed]
• Fabbri M, Garzon R, Cimmino A et al.: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. PNAS 2007; 104: 15805-10.[Crossref]

Identifiers

DOI

10.2478/v10035-009-0078-x